China688363.CG▼5
Bloomage Biotech first-half net profit attributable to parent 153 million yuan, down 30.8% year on year
Bloomage Biotech released its 2026 half-year report. First-half net profit attributable to the parent was 153 million yuan, down 30.8% year on year. Operating revenue was 1.756 billion yuan, down 22.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 129 million yuan, down 25.5% year on year. Net operating cash flow was 524 million yuan, up 140.1% year on year. Earnings per share were 0.32 yuan. In the second quarter, operating revenue was 927 million yuan, down 21.6% year on year, and net profit attributable to the parent was 88.13 million yuan, down 25.9% year on year. As of the end of the second quarter, total assets were 8.881 billion yuan, up 2.2% from the end of the previous year, and net assets attributable to the parent were 7.09 billion yuan, up 0.1% from the end of the previous year. The company said that during the reporting period, revenue from its dermatological science innovation and transformation business declined, causing total profit and net profit attributable to the parent to fall by more than 30% year on year. At the same time, the company is reshaping and upgrading its business model, with the raw materials business achieving modest growth and sales of medical terminal products and dermatological science innovation and transformation products being gradually optimized.
688363.CG · Capital · Negative First-half net profit fell 30.8% and revenue dropped 22.3% year on year.